Cumberland Pharmaceuticals CPIX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $44.52M+17.6% | $37.87M-4.3% | $39.55M-5.9% | $42.01M+16.7% | ||
| $6.67M+1.2% | $6.59M+8.6% | $6.07M-33.5% | $9.12M+3.5% | ||
| $37.85M+21.0% | $31.28M-6.6% | $33.49M+1.8% | $32.89M+21.0% | ||
| 85%+2.4pp | 82.6%-2.1pp | 84.7%+6.4pp | 78.3%+2.8pp | ||
| $5.57M+15.6% | $4.82M-17.4% | $5.83M-12.8% | $6.69M+17.7% | ||
| $19.1M+12.2% | $17.02M-7.7% | $18.45M+10.7% | $16.66M+11.0% | ||
| $11.95M+7.4% | $11.13M+4.5% | $10.65M+4.6% | $10.18M+4.1% | ||
| $4.03M-15.0% | $4.75M-41.4% | $8.1M+59.9% | $5.07M+15.9% | ||
| $47.31M+6.8% | $44.3M-9.8% | $49.11M+2.9% | $47.72M+9.3% | ||
| -$2.79M+56.6% | -$6.43M+32.7% | -$9.55M-67.5% | -$5.7M+25.7% | ||
| -6.3%+10.7pp | -17%+7.2pp | -24.2%-10.6pp | -13.6%+7.8pp | ||
| $495.99K-18.1% | $605.51K-9.3% | $667.86K+14.0% | $586K+498% | ||
| $476.75K+42.5% | $334.44K+16.6% | $286.85K+192% | $98.41K+277% | ||
| —— | $0— | —— | —— | ||
| -$2.81M+56.5% | -$6.47M-2.9% | -$6.28M-12.6% | -$5.58M-0.3% | ||
| $40.26K+278% | -$22.67K-150% | $45.77K-33.5% | $68.85K+97.3% | ||
| -$2.84M+56.2% | -$6.48M-3.2% | -$6.28M-12.7% | -$5.57M-58.8% | ||
| -6.4%+10.7pp | -17.1%-1.2pp | -15.9%-2.6pp | -13.3%-3.5pp | ||
| -$0.19+59.6% | -$0.47-6.8% | -$0.44-15.8% | -$0.38-58.3% | ||
| -$0.19+59.6% | -$0.47-6.8% | -$0.44-15.8% | -$0.38-58.3% | ||
| 60M+6.6% | 56.3M-2.4% | 57.7M-1.2% | 58.4M-2.9% | ||
| 59.7M+6.0% | 56.3M-1.7% | 57.3M-1.9% | 58.4M-2.2% | ||
| $4.03M-15.0% | $4.75M-41.4% | $8.1M+59.9% | $5.07M+15.9% | ||
| $44.52M+17.6% | $37.87M-4.3% | $39.55M-5.9% | $42.01M— | ||
| -$2.79M+56.6% | -$6.43M+32.7% | -$9.55M-67.5% | -$5.7M+25.7% | ||
| $1.35M+188% | -$1.53M+66.9% | -$4.62M-1,126% | -$376.82K+87.7% | ||
| $1.35M+188% | -$1.53M+66.9% | -$4.62M-1,126% | -$376.82K+87.7% | ||
| 3%+7.1pp | -4%+7.6pp | -11.7%-10.8pp | -0.9%+7.6pp | ||
| -$2.79M+56.6% | -$6.43M+32.7% | -$9.55M-67.5% | -$5.7M+25.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cumberland Pharmaceuticals's revenue?
- Cumberland Pharmaceuticals (CPIX) generated $41.9M in revenue over the trailing twelve months, up 2.1% year over year.
- Is Cumberland Pharmaceuticals profitable?
- Cumberland Pharmaceuticals is not currently profitable: it reported a net loss of $7.4M over the trailing twelve months, a -17.6% net margin.
- What are Cumberland Pharmaceuticals's profit margins?
- Gross margin is 82.9% and operating margin is -17.2%, with a -17.6% net margin.
- What is Cumberland Pharmaceuticals's earnings per share?
- Cumberland Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.49.
- Where does Cumberland Pharmaceuticals's income statement data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
